Login to Your Account



Partial Clinical Hold Shakes Vertex, Most Trials Will Continue

By Catherine Shaffer
Staff Writer

Monday, July 29, 2013
The FDA imposed a partial clinical hold on an ongoing Phase II study of Vertex Pharmaceuticals Inc.'s hepatitis C virus candidate, VX-135, due to observations of elevated liver enzymes in patients receiving a 400-mg dose of the drug in the trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription